INTRODUCTION
============

Gastric outlet obstruction (GOO), afferent limb syndrome (ALS), or biliary obstruction, in patients with altered gastrointestinal (GI) tract anatomy, are the most common presentations in clinical practice which require either surgical and/or endoscopic drainage. Traditionally, endoscopic dilation for benign etiologies and surgery for malignant etiologies has been the standard course of treatment \[[@b1-ce-2018-077]\]. However, endoscopic dilations require multiple sessions and have variable outcomes, including the risk of perforation \[[@b2-ce-2018-077]-[@b4-ce-2018-077]\]. Surgical bypass is limited by significant morbidity, prolonged recovery time, and high operative costs \[[@b5-ce-2018-077]-[@b7-ce-2018-077]\]. In cancer patients with poor surgical tolerance, endoscopic placement of self-expanding metallic stents (SEMS) is an alternative, but is limited by stent obstruction due to tumor ingrowth \[[@b1-ce-2018-077],[@b5-ce-2018-077]-[@b7-ce-2018-077]\]. The same may not even be feasible, if the obstruction has led to complete closure of the lumen.

Endoscopic creation of a *de-novo* anastomosis with the aid of lumen apposing metal stent (LAMS) is an exciting new technique. It is a less invasive alternative to surgery. It can be a therapeutic or palliative intervention depending on the etiology of obstruction. It enables drainage and efficient transit of GI contents (bile, pancreatic enzymes or food contents) by by-passing the site of obstruction which may be due to benign or malignant etiology.

The procedure entails endoscopic localization of two adjacent lumens of the GI tract bypassing the site of obstruction, followed by deployment of LAMS for formation of a fistulous tract. LAMS is a novel saddle shaped, 1-cm long stent, 10 or 15 mm in diameter with a wide flange of 23 and 28 mm on either end. The unique saddle shape of LAMS gives it anti-migratory property and allows it to hold the two GI lumens together. The application of LAMS in this clinical setting is an extension of its known indications, and experience thereof, is still evolving \[[@b8-ce-2018-077]-[@b10-ce-2018-077]\].

In this article we review the available evidence in form of case reports, case series, retrospective and prospective studies, describing the use of LAMS for *de-novo* GI anastomosis.

MATERIALS AND METHODS
=====================

An extensive English literature search till December 2017 was performed separately by two authors, using PubMed and Google Scholar, to identify peer reviewed original articles using keywords- Lumen apposing metal stent; Gastroenterostomy; Enteroenteric anastomosis. Only human study subject articles in English literature were selected. Additional relevant studies were identified by manually searching the references of pertinent studies.

RESULTS
=======

A preliminary search yielded 14 original studies which included 2 prospectively designed studies \[[@b11-ce-2018-077],[@b12-ce-2018-077]\], 3 retrospective studies \[[@b13-ce-2018-077]-[@b15-ce-2018-077]\], 3 case series \[[@b16-ce-2018-077]-[@b18-ce-2018-077]\], and 6 case reports \[[@b19-ce-2018-077]-[@b24-ce-2018-077]\]. On further reading of selected articles, 2 articles were excluded due to duplication of represented population \[[@b12-ce-2018-077],[@b15-ce-2018-077]\] and one article was excluded due to lack of data regarding the type of stent used \[[@b18-ce-2018-077]\]. The etiology and location of obstruction, technical procedure details, stent specifics, outcomes, and complications with their management from each study were reviewed and have been summarized in [Tables 1](#t1-ce-2018-077){ref-type="table"}, [2](#t2-ce-2018-077){ref-type="table"}, and [3](#t3-ce-2018-077){ref-type="table"}.

DISCUSSION
==========

Patient characteristics
-----------------------

### Demographics

Out of 11 studies, demographic data was reported in 9 studies \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b14-ce-2018-077],[@b16-ce-2018-077]-[@b21-ce-2018-077],[@b23-ce-2018-077],[@b24-ce-2018-077]\]. The mean age of the cohort was 62.9 years, with the range varying from as young as 34 years to as old as 90 years. The study cohort comprised of 50.7% males (38/75) and 49.3% females (37/75).

### Anatomy and indication

Almost half (51.9%) of the cohort had pre-existing altered GI anatomy \[[@b11-ce-2018-077],[@b16-ce-2018-077],[@b17-ce-2018-077],[@b19-ce-2018-077]-[@b23-ce-2018-077]\].

GOO was the most common indication attributed in 84.8% (67/79) of cases \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b14-ce-2018-077],[@b24-ce-2018-077]\]. The second most common indication was ALS, in 11.4% (9/79) cases \[[@b16-ce-2018-077],[@b17-ce-2018-077],[@b20-ce-2018-077],[@b21-ce-2018-077]\]. The two less common indications were to gain endoscopic access to relieve biliary obstruction (1.3%) \[[@b19-ce-2018-077]\] and efferent limb obstruction (2.5%) \[[@b22-ce-2018-077],[@b23-ce-2018-077]\]. In 74.7% cases, the underlying etiology was malignant \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b14-ce-2018-077],[@b16-ce-2018-077],[@b17-ce-2018-077],[@b19-ce-2018-077]-[@b21-ce-2018-077],[@b24-ce-2018-077]\], whereas in the rest it was benign (25.3%) \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b17-ce-2018-077],[@b22-ce-2018-077],[@b23-ce-2018-077]\].

### Prior interventions

No data was reported regarding prior interventions in 38% (30/79) of the cohort \[[@b14-ce-2018-077]\]. Endoscopic ultrasound (EUS)-guided *de-novo* anastomosis was the preferred as first line treatment in 26.6% (21/79) cases \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b16-ce-2018-077],[@b21-ce-2018-077]-[@b24-ce-2018-077]\], and as secondary treatment (after failed primary interventions) in 35.4% (28/79) patients \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b17-ce-2018-077],[@b19-ce-2018-077],[@b20-ce-2018-077]\]. Prior interventions included endoscopic dilation \[[@b11-ce-2018-077]\], SEMS \[[@b11-ce-2018-077],[@b13-ce-2018-077]\], percutaneous endoscopic gastrostomy or jejunostomy \[[@b11-ce-2018-077]\], nasal-jejunal tube \[[@b11-ce-2018-077]\], enteroscopy \[[@b17-ce-2018-077],[@b19-ce-2018-077]\], endoscopy \[[@b20-ce-2018-077]\], EUS-guided biliary drainage \[[@b19-ce-2018-077]\], percutaneous transhepatic biliary drainage \[[@b17-ce-2018-077],[@b19-ce-2018-077]\].

Demographics, details of underlying etiology, indication, anatomy, and prior interventions in patients from each individual study have been summarized in [Table 1](#t1-ce-2018-077){ref-type="table"}.

Procedure characteristics
-------------------------

### Technique

Multiple approaches exist to identify the target small bowel loop.

1.  1\. Incomplete occlusion:

2.  • Balloon or nasobiliary drain assisted: \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b14-ce-2018-077],[@b19-ce-2018-077],[@b23-ce-2018-077],[@b24-ce-2018-077]\] In this approach, the area of stenosis is traversed either by the endoscope itself or with a guidewire under fluoroscopic guidance ([Fig. 1](#f1-ce-2018-077){ref-type="fig"}). A balloon dilator or nasobiliary drain is then passed over the guidewire and the balloon is filled with contrast (or the nasobiliary drain is used to insufflate the lumen with water), which can then be localized by an echoendoscope in the stomach ([Fig. 2](#f2-ce-2018-077){ref-type="fig"}).

3.  • Hybrid rendezvous:11 In this approach, the area of stenosis is traversed by an ultra-thin scope, followed by water insufflation of the distal lumen, which can then be identified by an echoendoscope in the stomach.

4.  • EUS-guided balloon occluded gastro-jejunostomy bypass (EPASS): \[[@b14-ce-2018-077]\] In this approach, the area of stenosis is first traversed with a guidewire over which a special double balloon enteric tube is passed (Tokyo Medical University Type; Create Medic Co., Yokohama, Japan). The two balloons are then inflated with contrast, followed by saline infusion between the two balloons, which holds the small bowel in close proximity to the gastric lumen and allows easy identification by the echoendoscope.

```{=html}
<!-- -->
```
1.  2\. Complete or incomplete occlusion:

2.  • Direct technique: \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b14-ce-2018-077],[@b16-ce-2018-077],[@b17-ce-2018-077],[@b19-ce-2018-077]-[@b24-ce-2018-077]\] This approach is feasible even in cases where complete lumen obstruction prevents traversing of the site with a scope or a guidewire. The target small bowel loop is identified and confirmed by contrast injection with the help of EUS-guided needle puncture (19 or 22 G).

3.  • Natural orifice transluminal endoscopic surgery (NOTES): \[[@b11-ce-2018-077]\] This approach is feasible even in cases with complete luminal occlusion. Essentially, in this approach, a full thickness gastric wall incision is made followed by dilation to allow the endoscope to enter the peritoneal cavity, where under direct visualization, a small bowel loop is identified, incised, and a guidewire is placed, over which the stent is deployed. This approach does not require an echoendoscope.

In our study cohort, 43% (34/79) underwent the balloon-assisted method, 27.9% (22/79) underwent EPASS, 20.3% (16/79) underwent the direct technique, 6.3% (5/79) underwent the hybrid rendezvous technique, and 2.5% (2/79) underwent NOTES assisted *de-novo* entero-enteric or gastro-enteric anastomosis \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b14-ce-2018-077],[@b16-ce-2018-077],[@b17-ce-2018-077],[@b19-ce-2018-077]-[@b24-ce-2018-077]\]. Chen et al. compared the balloon-assisted and direct EUS-guided techniques and found similar clinical and technical success rates (TSRs), but the mean duration of the procedure was significantly lower in the direct technique (35.1+31.2 min) in contrast to the balloon-assisted technique (89.9+33.3 min) \[[@b15-ce-2018-077]\].

Once the target bowel loop has been identified, the next step depends on whether the intent is to use a cautery enhanced LAMS apparatus or non-cautery enhanced LAMS apparatus. The latter requires puncturing of the target lumen (if containing the contrast filled balloon, will leak into the puncture, thus helping to confirm the lumen location) with an EUS-guided needle (19 or 20 G). This is followed by passage of a guidewire (0.035 inch diameter), balloon dilation of the tract (it is not advisable to dilate more than 4--6 mm, as it may lead to spontaneous misplacement of LAMS), and then deployment of LAMS (distal flange first followed by the proximal flange). Conversely, cautery enhanced LAMS combines all these steps into one step ([Fig. 3](#f3-ce-2018-077){ref-type="fig"}). LAMS can be deployed under direct EUS guidance alone or in combination with fluoroscopy. Once the LAMS is deployed, a 10 or 15 mm balloon dilator is used to dilate the stent to its intended size. In our study cohort, two types of LAMS were used- Axios (non-cautery enhanced or hot) \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b14-ce-2018-077],[@b16-ce-2018-077],[@b17-ce-2018-077],[@b19-ce-2018-077]-[@b24-ce-2018-077]\] and Niti-S Spaxus \[[@b14-ce-2018-077]\]. In all, 53.2% (42/79) had non-cautery enhanced Axios stent, 44.3% (35/79) had hot Axios stent, and 2.5% (2/79) had Niti-S spaxus stent \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b14-ce-2018-077],[@b16-ce-2018-077],[@b17-ce-2018-077],[@b19-ce-2018-077]-[@b24-ce-2018-077]\]. The stent size and type for each study has been summarized in the [Table 2](#t2-ce-2018-077){ref-type="table"}.

As the small bowel is mobile, keeping the target loop stationary and in close proximity of the site of intended therapeutic intervention is challenging. To achieve stability, several approaches have been described:

1.  • Glucagon administration to decrease peristaltic movements

2.  • Snare-balloon technique- A snare is attached over the balloon catheter and is used to catch the guidewire passed through the EUS needle. This is followed by application of tension on the snare/balloon apparatus which helps to keep the target bowel loop fixed in place \[[@b13-ce-2018-077]\]. A modification of this technique was described by Ngamruengphong et al. where both ends of the guidewire are pulled (externally) to achieve the same outcome \[[@b18-ce-2018-077]\].

In addition, few authors chose to place a pigtail catheter through the LAMS to prevent any recurrence of obstruction \[[@b17-ce-2018-077],[@b20-ce-2018-077]\]. This practice has been shown to be useful at alternative sites like choledocho-enterostomy and cholecysto-enterostomy creation with LAMS \[[@b8-ce-2018-077],[@b9-ce-2018-077]\].

### Type of anastomosis

Majority of our cohort, i.e. 93.5% (73/78) had a gastro-enterostomy, whereas only a small fraction had entero-enterostomy (5/78) \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b14-ce-2018-077],[@b16-ce-2018-077],[@b17-ce-2018-077],[@b19-ce-2018-077]-[@b24-ce-2018-077]\].

All procedure and stent specific details for each study have been summarized in [Table 2](#t2-ce-2018-077){ref-type="table"}.

Outcomes
--------

### Follow up

Each author reported a variety of modalities to follow up their patient's post-procedure: either clinically alone or in combination with radiological studies like- upper GI series, computed tomography scan, or endoscopy. Similarly, a wide variation was noted in the follow up period across the studies as has been summarized in the [Table 3](#t3-ce-2018-077){ref-type="table"}.

### Technical success and failure

Technical success was defined by adequate placement of LAMS. In total, 79 patients from 11 individual studies underwent EUS-guided *de-novo* entero-enteric anastomosis. Composite TSR for the cohort was 91.1% (72/79). Individual TSR was 100% for eight studies \[[@b16-ce-2018-077],[@b17-ce-2018-077],[@b19-ce-2018-077]-[@b24-ce-2018-077]\]. For the remaining three, the TSR was 92% (24/26), 90% (9/10), and 87% (26/30), respectively \[[@b11-ce-2018-077],[@b13-ce-2018-077],[@b14-ce-2018-077]\]. Tyberg et al. reported initial misplacement of LAMS in 7 patients (7/26) \[[@b11-ce-2018-077]\]. The authors were able to successfully bridge the stent in majority of cases (5/7) with the aid of fully covered SEMS (3/5), LAMS (1/5), or NOTES (1/5) \[[@b11-ce-2018-077]\]. Out of the patients who had technical failure (7/79), 8.9% were managed with SEMS (4/7), over the scope clip (1/7), and surgical gastro-jejunostomy (SGJ- 2/7). Half the patients with SEMS (2/4) experienced migration of the stent and consequently underwent SGJ. In a retrospective comparative study by Khashab et al. the TSR for SGJ was significantly (*p*\<0.009) higher in contrast to that for EUS-guided gastro-enterostomy (EUS-GE) \[[@b14-ce-2018-077]\]. No significant predictors for technical success were found after adjustments for age, gender, etiology, prior interventions, presence or absence of altered anatomy, and use of LAMS with or without cautery for fistula creation \[[@b11-ce-2018-077]\].

### Clinical success and failure

Clinical success was defined as the ability of the patient to tolerate oral feeds/alleviation of obstructive symptoms after successful placement of LAMS. Out of 72 patients who underwent successful placement of LAMS and creation of new entero-enteric anastomosis, 97.2% (70/72) had clinical success. Individual clinical success rate (CSR) was 100% for all studies \[[@b13-ce-2018-077],[@b14-ce-2018-077],[@b16-ce-2018-077],[@b17-ce-2018-077],[@b19-ce-2018-077]-[@b24-ce-2018-077]\] except one \[[@b11-ce-2018-077]\]. Two patients (2.8%) had persistent nausea/vomiting post procedure requiring enteral feeding despite a patent stent \[[@b11-ce-2018-077]\].

Khashab et al. reported a higher CSR for EUS-GE group (100%) in contrast to that for the SGJ group (90%), but this difference lacked statistical significance \[[@b14-ce-2018-077]\]. No significant predictors of clinical success were found after adjustments for age, gender, etiology, presence or absence of altered anatomy, prior interventions, and use of LAMS with or without cautery for fistula creation \[[@b11-ce-2018-077]\].

Combined technical and clinical success was achieved in 88.6% (70/79) of the study cohorts (*n*=79).

### Recurrence

For the study cohort, over the study specific follow-up period, 97.2% of patients (70/72) remained free of obstructive symptoms. Two patients (2.8%) had recurrence at day 88 (post procedure) and at 3 months (post LAMS removal), respectively \[[@b14-ce-2018-077],[@b17-ce-2018-077]\]. The first patient had obstruction secondary to a food bolus and was managed with endoscopic extraction \[[@b14-ce-2018-077]\]. The second patient had re-stenosis at the site (4 months post procedure) and was successfully managed with re-insertion of LAMS. The underlying etiology was benign \[[@b17-ce-2018-077]\] and malignant \[[@b14-ce-2018-077]\], respectively, in these two cases. Compared to EUS-GE cohort (1/26), the SGJ cohort (9/63) had a much higher absolute recurrence although statistical significance was lacking (*p*=0.081) \[[@b14-ce-2018-077]\].

#### Complications

1\. Abdominal pain: Only significant pain requiring hospitalization was considered as an adverse event. In all, 3.8% (3/79) had significant abdominal pain. Two of them improved with supportive care alone \[[@b14-ce-2018-077]\]. One patient underwent diagnostic laparoscopy with no obvious cause and at the discretion of surgeon, underwent SGJ \[[@b11-ce-2018-077]\].

2\. Peritonitis: Overall, 0.7% (1/79) of patients developed this adverse event. The patient had a malignancy, ascites, and peritoneal carcinomatosis, and he died the following day \[[@b11-ce-2018-077]\].

3\. Bleeding: In total, 0.7% (1/79) of patients had this adverse event. This patient was successfully managed with conservative management, including blood transfusion \[[@b11-ce-2018-077]\].

All outcomes for each individual study have been summarized in [Table 3](#t3-ce-2018-077){ref-type="table"}.

CONCLUSIONS
===========

*De-novo* creation of gastro-enteric or entero-enteric anastomosis with the help of LAMS for patients with GOO, ALS, biliary obstruction among subjects with altered anatomy, and efferent limb obstruction, is a novel, less invasive alternative to surgery. It has been successfully used as the primary (preferred) or secondary (after prior treatment failure) treatment in management of patients with either malignant or benign etiology. The composite technical and CSR for our study cohort was 91.1% and 97.2%, respectively. Only 2.8% had recurrence of symptoms and about 6.3% had some significant complications (bleeding, abdominal pain, or peritonitis). The procedure is new and various techniques have been described and used to achieve the desired outcome. It is advisable that the procedure be done only by experts at centers of excellence with adequate surgical back-up.
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![Introduction of the guidewire. (A) Endoscopic view of the duodenal stenosis. (B) Fluoroscopic view of the guidewire introduced through the stenosis of the small bowel. (C) Fluoroscopic view of a 20-mm balloon dilator inflated with contrast fluid within the small bowel (Re-produced with permission from Thieme publishers).](ce-2018-077f1){#f1-ce-2018-077}

![The balloon dilator inside the small bowel loop. (A) Fluoroscopic view of the echoendoscope in the stomach next to the inflated balloon within the adjacent jejunal loop. (B) Echoendoscopic view showing the inflated balloon. (C) Echoendoscope view showing the inflated balloon (\*), the tip of the delivery system of the stent (fat arrow) inside the jejunal lumen (\*\*), and the gastric wall (thin arrow) (Re-produced with permission from Thieme publishers).](ce-2018-077f2){#f2-ce-2018-077}

![Deployment of the stent. (A) Echoendoscopic view of the released distal flange of the stent (arrows) into the lumen of the jejunal loop. (B) Fluoroscopic view of the fully released stent (circle) and the intact balloon (Re-produced with permission from Thieme publishers).](ce-2018-077f3){#f3-ce-2018-077}

###### 

Patient Characteristics across Each Study

  Study/Location                                                          Study type                                            No.                                              Age (yr)                                              Gender distribution (M/F)   Anatomy                                         Indication                                                                 Prior interventions
  ----------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------ ----------------------------------------------------- --------------------------- ----------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------
  Tyberg et al. (2016) \[[@b11-ce-2018-077]\] USA and Spain               Prospective                                           26                                               Mean age: 66.2 (range, 34--90)                        M: 11                       Altered anatomy: 8/26                           GOO: 26/26                                                                 N: 21/26
  F: 15                                                                   1\. Whipple: 3/8                                      Etiology:                                        1\. SEMS: 13/21                                                                                                                                                                                              
  2\. Sub-total gastrectomy: 1/8                                          1\. Malignant- 17/26                                  2\. Dilation: 3/21                                                                                                                                                                                                                                            
  3\. Gastro-jejunal bypass: 1/8                                          2\. Benign- 9/26                                      3\. PEG-J or naso-jejunal tube placement: 5/21                                                                                                                                                                                                                
  4\. Roux-en-Y bypass: 2/8                                                                                                                                                                                                                                                                                                                                                                   
  5\. Billroth 1: 1/8                                                                                                                                                                                                                                                                                                                                                                         
  Khashab et al. (2015) \[[@b13-ce-2018-077]\] USA (2 center)             Retrospective                                         10                                               Mean age: 55.8 (range, 48--81)                        M: 7                        Normal                                          GOO: 10/10                                                                 N: 1/10
  F: 3                                                                    Etiology:                                             1\. SEMS                                                                                                                                                                                                                                                      
  1\. Malignant: 3/10                                                                                                                                                                                                                                                                                                                                                                         
  2\. Benign: 7/10                                                                                                                                                                                                                                                                                                                                                                            
  Khashab et al. (2017) \[[@b14-ce-2018-077]\] USA and Japan (4 center)   Retrospective                                         EUS-GE: 30                                       Mean age: 70±13.3                                     M: 17                       Normal                                          GOO:                                                                       DNA
  F: 13                                                                   Etiology:                                                                                                                                                                                                                                                                                                           
  1\. Malignant: 30/30                                                                                                                                                                                                                                                                                                                                                                        
  SGJ: 63                                                                 Mean age: 68±9.6 (*p*=0.8)                            M: 32                                            Normal                                                GOO:                        DNA                                                                                                                        
  F: 31                                                                   Etiology:                                                                                                                                                                                                                                                                                                           
  (*p*=0.6)                                                               1\. Malignant: 63/63                                                                                                                                                                                                                                                                                                
  Taunk et al. (2015) \[[@b16-ce-2018-077]\] USA                          Case series                                           3                                                DNA                                                   DNA                         Pancreatico-duodenostomy (pancreatic cancer)    Acute afferent loop syndrome (recurrent pancreatic cancer)                 None
  Rodrigues-Pinto et al. (2016) \[[@b17-ce-2018-077]\] USA                Case series                                           4                                                Mean age: 58.75 (range, 55--63)                       M: 1                        Roux-en-Y anatomy: 4/4                          Afferent loop syndrome: 4/4                                                1\. Enteroscopy (failed)
  F: 3                                                                    Etiology:                                             Etiology:                                        2\. Percutaneous transhepatic biliary drainage: 3/4                                                                                                                                                          
  1\. Pancreatic adenocarcinoma: 3/4                                      1\. Malignant: 2/4                                                                                                                                                                                                                                                                                                  
  2\. Cholangiocarcinoma: ¼                                               2\. Post-operative persistent anastomotic leak: 1/4                                                                                                                                                                                                                                                                 
  3\. Benign stricture: 1/4                                                                                                                                                                                                                                                                                                                                                                   
  Perez-Miranda et al. (2014) \[[@b19-ce-2018-077]\] Spain                Case report                                           1                                                65                                                    M: 1                        Roux-en-Y anatomy (Klatskin tumor)              Biliary obstruction (recurrent Klatskin tumor)                             1\. Percutaneous biliary drainage
  2\. EUS-guided biliary drainage                                                                                                                                                                                                                                                                                                                                                             
  3\. Enteroscopy based ERCP                                                                                                                                                                                                                                                                                                                                                                  
  Shah et al. (2015) \[[@b20-ce-2018-077]\] USA                           Case report                                           1                                                44                                                    F: 1                        Whipple (pancreatic cancer)                     Afferent loop syndrome (recurrent pancreatic cancer)                       Endoscopy (unable to traverse with scope or guidewire)
  Ikeuchi et al. (2015) \[[@b21-ce-2018-077]\] Japan                      Case report                                           1                                                74                                                    F: 1                        Pancreatico-duodenostomy (cholangiocarcinoma)   Afferent loop syndrome (recurrent cholangiocarci- noma)                    None
  Majmudar et al. (2016) \[[@b22-ce-2018-077]\] USA                       Case report                                           1                                                DNA                                                   DNA                         Roux-en-Y (gastric bypass)                      Complete jejunal obstruction (complication post bypass revision surgery)   None
  Küllmer et al. (2017) \[[@b23-ce-2018-077]\] USA                        Case report                                           1                                                51                                                    M: 1                        Roux-en-Y (gastric cancer)                      Efferent limb obstruction (kinking)                                        None
  Tarantino et al. (2017) \[[@b24-ce-2018-077]\] Italy                    Case report                                           1                                                81                                                    F: 1                        Normal                                          GOO (pancreatic adenocarcinoma)                                            None

SEMS, self-expanding metallic stents; PEG-J, percutaneous endoscopic gastrostomy or jejunostomy; GOO, gastric outlet obstruction; EUS-GE, endoscopic ultrasound-guided gastro-enterostomy; DNA, data not available; SGJ, surgical gastro-jejunostomy; ERCP, endoscopic retrograde cholangiopancreatography.

###### 

Procedure and Stent Characteristics across Each Study

  Study/Location                                                          No.                                                               Site of intervention                              Procedure technique                    LAMS specifics                     Duration of procedure
  ----------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------- -------------------------------------- ---------------------------------- -----------------------------------
  Tyberg et al. (2016) \[[@b11-ce-2018-077]\] USA and Spain               26                                                                Gastro-jejunostomy                                Techniques:                            1\. Cautery tipped LAMS: 9/26      DNA
  1\. Balloon or nasobiliary drain assisted: 16/26                        2\. Non-cautery tipped LAMS: 17/26                                                                                                                                                            
  2\. Hybrid rendezvous: 5/26                                                                                                                                                                                                                                           
  3\. Direct: 3/26                                                        Diameter:                                                                                                                                                                                     
  4\. Natural orifice transluminal endoscopic surgery: 2/26               1\. 10 mm: 1/26                                                                                                                                                                               
  2\. 15 mm: 25/26                                                                                                                                                                                                                                                      
  Khashab et al. (2015) \[[@b13-ce-2018-077]\] USA (2 center)             10                                                                1\. Gastro-jejunosto- my: 6/9                     Techniques:                            1\. Non-cautery tipped LAMS: 9/9   Mean: 96 minutes (range, 45--152)
  2\. Gastro-duodenostomy: 3/9                                            1\. Balloon assisted: 9/10                                        D: 15 mm                                                                                                                    
  2\. Direct: 1/10                                                                                                                                                                                                                                                      
  Khashab et al. (2017) \[[@b14-ce-2018-077]\] USA and Japan (4 center)   EUS-GE: 30                                                        1\. Gastro-jejunostomy                            1\. Balloon-assisted technique: 6/30   1\. Cautery tipped LAMS: 21/30     DNA
  2\. Gastro-duodenostomy                                                 2\. EUS-guided balloon-occluded gastrojejunostomy bypass: 22/30   2\. Non-cautery tipped LAMS: 7/30                                                                                           
  3\. Direct: 2/30                                                        3\. Niti-S Spaxus stent: 2/30                                                                                                                                                                 
  SGJ: 63                                                                 Gastro-jejunostomy                                                Surgical open retrocolic or antecolic technique   N/A                                    DNA                                
  Taunk et al. (2015) \[[@b16-ce-2018-077]\] USA                          3                                                                 Gastro-jejunostomy                                Direct technique: 3/3                  Non-cautery tipped                 DNA
  LAMS                                                                                                                                                                                                                                                                  
  D: 15 mm                                                                                                                                                                                                                                                              
  Rodrigues-Pinto et al. (2016) \[[@b17-ce-2018-077]\] USA                4                                                                 1\. Gastro-jejunostomy: 2/4                       Direct technique: 4/4                  1\. Cautery tipped LAMS: 2/4       DNA
  2\. Jejuno-jejunostomy: 1/4                                             2\. Non-cautery tipped LAMS: 2/4                                                                                                                                                              
  3\. Duodeno-jejunostomy: 1/4                                                                                                                                                                                                                                          
  Diameter:                                                                                                                                                                                                                                                             
  1\. 10 mm: 3/4                                                                                                                                                                                                                                                        
  2\. 15 mm: 1/4                                                                                                                                                                                                                                                        
  Perez-Miranda et al. (2014) \[[@b19-ce-2018-077]\] Spain                1                                                                 Duodeno-jejunostomy                               Nasobilliary drain-assisted            Non-cautery tipped                 DNA
  LAMS                                                                                                                                                                                                                                                                  
  D: 15 mm                                                                                                                                                                                                                                                              
  Shah et al. (2015) \[[@b20-ce-2018-077]\] USA                           1                                                                 Gastro-jejunostomy                                Direct technique                       Non-cautery tipped                 DNA
  LAMS                                                                                                                                                                                                                                                                  
  D: 15 mm                                                                                                                                                                                                                                                              
  Ikeuchi et al. (2015) \[[@b21-ce-2018-077]\] Japan                      1                                                                 Gastro-jejunostomy                                Direct technique                       Cautery tipped LAMS                DNA
  D: 8 mm                                                                                                                                                                                                                                                               
  Majmudar et al. (2016) \[[@b22-ce-2018-077]\] USA                       1                                                                 Jejuno-jejunostomy                                Direct technique                       Non-cautery tipped                 DNA
  LAMS                                                                                                                                                                                                                                                                  
  D: 15 mm                                                                                                                                                                                                                                                              
  Küllmer et al. (2017) \[[@b23-ce-2018-077]\] USA                        1                                                                 Jejuno-jejunostomy                                Balloon-assisted technique             Cautery tipped LAMS                DNA
  D: 15 mm                                                                                                                                                                                                                                                              
  Tarantino et al. (2017) \[[@b24-ce-2018-077]\] Italy                    1                                                                 Gastro-jejunostomy                                Balloon-assisted technique             Cautery tipped LAMS                DNA
  D: 15 mm                                                                                                                                                                                                                                                              

LAMS, lumen apposing metal stent; DNA, data not available; EUS-GE, endoscopic ultrasound-guided gastro-enterostomy; SGJ, surgical gastro-jejunostomy; N/A, not available.

###### 

Summary of Outcomes for Each Individual Study

  Study/Location                                                          No.                                              Indication                                                                                Technical success                                Clinical success           Complications                Follow up
  ----------------------------------------------------------------------- ------------------------------------------------ ----------------------------------------------------------------------------------------- ------------------------------------------------ -------------------------- ---------------------------- ----------------------------------------------------------------------------------
  Tyberg et al. (2016) \[[@b11-ce-2018-077]\] USA and Spain               26                                               GOO: 26/26                                                                                Composite success: 24/26 (92%)                   Composite: 22/24 (91.7%)   Composite N: 3/26 (11.5%)    1\. Mean duration: 7.9 weeks (range, 0--32)
  Etiology:                                                               1\. Misplaced stents- 7/26                       1\. Persistent nausea/vomit- ing requiring enteral feeding (despite patent stent): 2/2    1\. Peritonitis: 1/3 (death the following day)   2\. Modality: clinically                                
  1\. Malignant- 17/26                                                    i\. Successfully bridged: 5/7                    2\. Bleeding: 1/3 (success with supportive care)                                                                                                                                                   
  2\. Benign- 9/26                                                        a\. FCSEMS: 3/5                                  3\. Pain: 1/3 (laparotomy revealed correctly placed LAMS)                                                                                                                                          
  b\. LAMS: 1/5                                                                                                                                                                                                                                                                                                               
  c\. NOTES: 1/5                                                                                                                                                                                                                                                                                                              
  ii\. Failure: 2/7                                                                                                                                                                                                                                                                                                           
  a\. OTSC: 1/2                                                                                                                                                                                                                                                                                                               
  b\. SEMS: 1/2                                                                                                                                                                                                                                                                                                               
  Khashab et al. (2015) \[[@b13-ce-2018-077]\] USA (2 center)             10                                               GOO: 10/10                                                                                9/10 (90%)                                       9/9 (100%)                 None                         1\. Mean duration: 150 days (range, 96--227)
  Etiology:                                                                                                                2\. Modality: clinically                                                                                                                                                                           
  1\. Malignant: 3/10                                                     Failure: 1/10                                                                                                                                                                                                                                       
  2\. Benign: 7/10                                                        Treated with:                                                                                                                                                                                                                                       
                                                                          i\. SEMS: 1/1 (stent migration, underwent SGJ)                                                                                                                                                                                                      
  Khashab et al. (2017) \[[@b14-ce-2018-077]\] USA and Japan (4 center)   EUS-GE: 30                                       GOO:                                                                                      1\. Composite success: 26/30 (87%)               26/26 (100%)               1\. Composite: 5/30 (16%)    1\. Mean duration: 115±63 days
  Etiology:                                                               2\. Failure: 4/30                                i\. Stent misdeployment: 3/5 (successful management with antibiotics and stent removal)   2\. Modality: clinical                                                                                   
  1\. Malignant: 30/30                                                    Treated with:                                    ii\. Abdominal pain (requiring hospitalization): 2/5 (managed conservatively)                                                                                                                      
  i\. SEMS: 2/4 (1/2 had stent migration, underwent SGJ)                  2\. Severity:                                                                                                                                                                                                                                       
  i\. Mild: 2/5                                                                                                                                                                                                                                                                                                               
  ii\. Moderate: 0                                                                                                                                                                                                                                                                                                            
  ii\. SGJ: 2/4                                                           iii\. Severe: 3/5                                                                                                                                                                                                                                   
                                                                          SGJ: 63                                          GOO:                                                                                      1\. Composite success: 63/63 (100%) *p*=0.009    57/63 (90%)                1\. Composite: 16/63 (25%)   1\. Mean duration: 196±155 days (*p*=0.02)
                                                                          Etiology:                                        OR 0.8 (CI, 0.44--7.07) *p*=0.18                                                          i\. Infection: 8/16                                                                                      
                                                                          1\. Malignant: 63/63                             ii\. Anastomotic leak: 4/16                                                               2\. Modality: clinical                                                                                   
                                                                          iii\. Ileus: 1/16                                                                                                                                                                                                                                   
                                                                          iv\. Agitation/Delirium: 2/16                                                                                                                                                                                                                       
                                                                          v\. Pulmonary embolism: 1/16                                                                                                                                                                                                                        
                                                                          2\. Severity:                                                                                                                                                                                                                                       
                                                                          i\. Mild: 13/16                                                                                                                                                                                                                                     
                                                                          ii\. Moderate: 3/16                                                                                                                                                                                                                                 
                                                                          iii\. Severe: 0                                                                                                                                                                                                                                     
  Taunk et al. (2015) \[[@b16-ce-2018-077]\] USA                          3                                                1\. Acute afferent loop syndrome (recurrent pancreatic cancer)                            3/3 (100%)                                       3/3 (100%)                 None                         DNA
  Rodrigues-Pinto et al. (2016) \[[@b17-ce-2018-077]\] USA                4                                                Afferent loop syndrome: 4/4                                                               4/4 (100%)                                       4/4 (100%)                 None                         1\. Duration range: 1--4 mo
  Etiology:                                                               2\. Modality:                                                                                                                                                                                                                                       
  1\. Malignant: 2/4                                                      i\. Imaging: 1/4                                                                                                                                                                                                                                    
  2\. Post-operative persistent anastomotic leak: 1/4                     ii\. Clinical: 4/4                                                                                                                                                                                                                                  
                                                                                                                           3\. Benign stricture: 1/4                                                                                                                                                                          iii\. Endoscopy: 1/4
  Perez-Miranda et al. (2014) \[[@b19-ce-2018-077]\] Spain                1                                                Biliary obstruction (recurrent Klastkin tumor)                                            1/1 (100%)                                       1/1 (100%)                 None                         1\. Duration: 90 days (pt died due to jejunal metastasis causing re-obstruction)
  Shah et al. (2015) \[[@b20-ce-2018-077]\] USA                           1                                                Afferent loop syndrome (recurrent pancreatic cancer)                                      1/1 (100%)                                       1/1 (100%)                 None                         1\. Duration: DNA
  2\. Modality: clinically                                                                                                                                                                                                                                                                                                    
  Ikeuchi et al. (2015) \[[@b21-ce-2018-077]\] Japan                      1                                                Afferent loop syndrome (recurrent cholangiocarcinoma)                                     1/1 (100%)                                       1/1 (100%)                 None                         1\. Duration: DNA
  2\. Modality: clinically and radiology (CT scan)                                                                                                                                                                                                                                                                            
  Majmudar et al. (2016) \[[@b22-ce-2018-077]\] USA                       1                                                Complete jejunal obstruction (complication post bypass revision surgery)                  1/1 (100%)                                       1/1 (100%)                 None                         1\. Duration: 3 mo
  2\. Modality: upper GI series                                                                                                                                                                                                                                                                                               
  Küllmer et al. (2017) \[[@b23-ce-2018-077]\] USA                        1                                                Efferent limb obstruction (kinking)                                                       1/1 (100%)                                       1/1 (100%)                 None                         1\. Duration: 4 mo
  2\. Modality: Endoscopy and radiology (contrast study)                                                                                                                                                                                                                                                                      
  Tarantino et al. (2017) \[[@b24-ce-2018-077]\] Italy                    1                                                GOO (pancreatic adenocarcinoma)                                                           1/1 (100%)                                       1/1 (100%)                 None                         1\. Duration: DNA
  2\. Modality: CT scan                                                                                                                                                                                                                                                                                                       

GOO, gastric outlet obstruction; FCSEMS, fully covered self-expanding metallic stents; LAMS, lumen apposing metal stent; NOTES, natural orifice transluminal endoscopic surgery; OTSC, over the scope clip; EUS-GE, endoscopic ultrasound-guided gastro-enterostomy; SGJ, surgical gastro-jejunostomy; OR, odds ratio; CI, confidence interval; DNA, data not available; CT, computed tomography; GI, gastrointestinal.
